Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03154346
Other study ID # 2017-BL-001
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date March 29, 2017
Est. completion date December 2023

Study information

Verified date November 2022
Source Baseline Study LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

This study is the first initiative of Project Baseline, a broader effort designed to develop a well-defined reference, or "baseline," of good health as well as a rich data platform that may be used to better understand the transition from health to disease and identify additional risk factors for disease. Project Baseline endeavors to test and develop new tools and technologies to collect, organize, and activate health information.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 10000
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 - U.S. Resident - Able to speak and read English - Willing and able to comply with all aspects of the protocol Exclusion Criteria: - Individuals working on Project Baseline, including the Baseline Study - Known severe allergy to nickel or metal jewelry

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Duke University School of Medicine Durham North Carolina
United States Duke University School of Medicine Kannapolis North Carolina
United States Baseline Study South San Francisco California
United States Stanford Medicine Stanford California
United States California Health and Longevity Institute Westlake Village California

Sponsors (5)

Lead Sponsor Collaborator
Baseline Study LLC Duke University, Google LLC., Stanford University, Verily Life Sciences LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Develop a set of scalable and standardized tools for acquiring, organizing, and analyzing clinical, molecular, imaging, sensor, self-reported, behavioral, environmental, and other health-related measurements For the duration of the study
Primary Evaluate the use of sensor technologies for the collection of continuous, accurate health information For the duration of the study
Primary Create a dataset encompassing a wide spectrum of phenotypic measures for future exploratory analysis For the duration of the study
Primary Measure the phenotypic diversity observed among a participant population, defining a range of expected values for multiple types of data For the duration of the study
Primary Identify biomarkers of disease-related transitions, including those related to cardiovascular disease and cancer For the duration of the study
See also
  Status Clinical Trial Phase
Recruiting NCT05016947 - Venetoclax Plus Inotuzumab for B-ALL Phase 1
Recruiting NCT05009537 - Optical Genome Mapping in Hematological Malignancies
Terminated NCT01230788 - Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia N/A
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Recruiting NCT05461625 - ACL Reconstruction With/Without ALL Reconstruction N/A
Recruiting NCT02990572 - Amish/Mennonite Research Contact Registry
Completed NCT02631993 - Photochemotherapy and Graft-versus-leukemia in Acute-leukemia N/A
Completed NCT00863148 - Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) Phase 2
Recruiting NCT04601584 - GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL Phase 1/Phase 2
Not yet recruiting NCT05592470 - commd7 Gene Expression in ALL
Recruiting NCT02861209 - Collaborative Network to Take Responsibility for Oral Anticancer Therapy N/A
Completed NCT01012492 - Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT Phase 2
Recruiting NCT04644016 - Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders Phase 2
Recruiting NCT06131801 - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recruiting NCT05476770 - Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Phase 1
Recruiting NCT03571321 - Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia Phase 1
Recruiting NCT05414162 - Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
Terminated NCT01532635 - A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives Phase 2
Completed NCT01319864 - POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients Phase 1
Completed NCT00013533 - Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies Early Phase 1